Ana Limon

Direttore Tecnico/Scientifico/R&S presso ORYZON GENOMICS S.A.

Health Technology

Consumer Services

Retail Trade

Profilo

Ana Limon is currently working as the SVP-Clinical Development & Global Medical Affairs at Oryzon Genomics SA. Previously, she held the position of Senior Director at Deciphera Pharmaceuticals, Inc. and Head-Global Medical Affairs & Oncology Pipeline at Takeda Farmacéutica España SA. Dr. Limon obtained a doctorate degree from the University of Barcelona.

Posizioni attive di Ana Limon

Società	Posizione	Inizio
ORYZON GENOMICS S.A.	Direttore Tecnico/Scientifico/R&S	11/01/2022

Tutte le posizioni attive di Ana Limon

Precedenti posizioni note di Ana Limon

Società	Posizione	Fine
Takeda Farmacéutica España SA Takeda Farmacéutica España SA Drugstore ChainsRetail Trade Part of Takeda Pharmaceutical Co., Ltd., Takeda Farmacéutica España SA is a pharmaceutical company based in Madrid, Spain. The Spanish company specializes in sales of pharmaceutical products.	Direttore Tecnico/Scientifico/R&S	-
DECIPHERA PHARMACEUTICALS, INC.	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Ana Limon

Formazione di Ana Limon

University of Barcelona

Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Ana Limon

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
ORYZON GENOMICS S.A.	Health Technology

Aziende private	2
Takeda Farmacéutica España SA Takeda Farmacéutica España SA Drugstore ChainsRetail Trade Part of Takeda Pharmaceutical Co., Ltd., Takeda Farmacéutica España SA is a pharmaceutical company based in Madrid, Spain. The Spanish company specializes in sales of pharmaceutical products.	Retail Trade
Deciphera Pharmaceuticals, Inc. Deciphera Pharmaceuticals, Inc. BiotechnologyHealth Technology Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. The company was founded by Peter A. Petillo and Daniel L. Flynn in 2003 and is headquartered in Waltham, MA.	Health Technology